GLRA3
ENSG00000145451
Target class
Ion channel
Chromosome
4
- Chemical probe available
- No
- Target name
- GLRA3
- Gene name
- Glycine receptor alpha 3
- Gene symbol
- GLRA3
- Protein name
- Glycine receptor subunit alpha-3
- Gene biotype
- Protein coding
- Gene family
- Glycine receptors
- Target class
- Ion channel
- Target type
- Human gene
- Tissues expressed in
- 4
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 3.39
- Tissue specificity (Gini)
- 0.839
- Tissue specificity (tau)
- 0.928
- KEGG gene identifiers
- hsa:8001
- Reactome pathways
- R-HSA-112314
- Protein interaction confidence
- 0.837
- Protein interaction partners
- 2
- End position
- 174829247
- Start position
- 174636920
- Chromosome
- 4
- Strand
- Reverse
- Postsynaptic cell membrane
- Multi-pass membrane protein . Perikaryon . Cell projection, dendrite . Synapse . Cell membrane
- Multi-pass membrane protein . Note=Partially colocalizes with GPHN that is known to mediate receptor clustering at postsynaptic membranes. .
- Plasma membrane
- PubMed 26416729
- PubMed 9677400
- Tissue specificity (tau)
- 0.927868
- Expression inequality (Gini)
- 0.838543
Expression in transcripts per million
- Brain - Frontal Cortex (BA9)
- 3.39
- Brain - Hypothalamus
- 2.77
- Brain - Cortex
- 2.28
- Brain - Anterior cingulate cortex (BA24)
- 1.98
- Brain - Substantia nigra
- 0.96
Expression in transcripts per million
- Brain - Frontal Cortex (BA9)3.39
- Brain - Hypothalamus2.77
- Brain - Cortex2.28
- Brain - Anterior cingulate cortex (BA24)1.98
- Brain - Substantia nigra0.96
- Brain - Amygdala0.94
- Pituitary0.88
- Brain - Nucleus accumbens (basal ganglia)0.77
- Testis0.6
- Brain - Caudate (basal ganglia)0.41
- Brain - Hippocampus0.29
- Brain - Putamen (basal ganglia)0.16
- Brain - Cerebellum0.15
- Brain - Spinal cord (cervical c-1)0.12
- Breast - Mammary Tissue0.08
- Small Intestine - Terminal Ileum0.06
- Brain - Cerebellar Hemisphere0.05
- Cervix - Endocervix0.04
- Uterus0.04
- Skin - Sun Exposed (Lower leg)0.04
- Esophagus - Muscularis0.03
- Pancreas0.03
- Esophagus - Gastroesophageal Junction0.03
- Spleen0.03
- Lung0.03
And 29 more, listed on the interactive page.
- GO:0051260
- GO:1902476
- GO:0005886
- GO:0016935
- GO:0005515
- GO:0016934
- GO:0022852
Related records
Trials (347)
- A Laboratory Model of Increasing Delta-9-tetrahydrocannabinol (THC) Potency on Cigarette Smoking
- A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome
- A Pilot Study of Dronabinol for Adult Patients With Primary Gliomas
- A RCT Comparing Dronabinol to a Placebo for Post-operative Pain in Total Joint Arthroplasty
- A Relative Bioavailability Study of 60 mg Nifedipine ER Tablets Under Non-fasting Conditions
- A Relative Bioavailability Study of 60 mg Nifedipine Extended Release Tablets Under Fasting Conditions
- A Study Examining the Use of Vaginal Nifedipine With Pelvic Floor Physical Therapy for Levator Myalgia and Pelvic Pain
- A Study of Cybis™ 10:25 THC:CBD Oil in Adults With Chronic Back/Neck Pain
- A Study of Nifecardia SRFC and Adalat OROS in the Treatment of Patients With Essential Hypertension
- A Study Of Synthetic THC And Sleep
- A Study of the Abuse Potential of Dronabinol in Recreational Cannabinoid Users
- A Study Testing the Safety and Effects of Single Doses of S1-221 in Healthy Volunteers
- Abuse Potential of Sativex
- Activation of the Endocannabinoid System and Cognition
- Acute Effects of Cannabis on Cognition and Affect
- Acute Effects of THC in Older Adult
- Adalat XL vs Diltiazem on Proteinuria and Blood Pressure in Hypertensive Diabetic Patients
- Add on Study on Δ9-THC Treatment for Posttraumatic Stress Disorders (PTSD)
- Age-dependent Effects of Smoked and Oral Delta-9-THC
- Age-Related Effects of THC
Drugs (4)
- Dronabinol
- Nifedipine
- Onternabez
- Strychnine